From the editor with Ascom PMC On March 2, 2024
Qdenga (TAK-003) is an immunomodulator developed by the Japanese laboratory Takeda Pharma. Vaccinating agent registration was approved by the National Health Surveillance Agency (Anvisa) in March 2023.
The vaccine contains live attenuated dengue viruses. Therefore, it stimulates immune responses against the four serotypes of dengue virus. The vaccine is administered in two doses, with an interval of three months between applications.
With different opening hours, the three points set up for multiple vaccination will also provide doses of immunization agents from the national immunization calendar.
Vaccination points for this Saturday:
*Ladera Health Center
From 8 am to 6 pm
*UPS Simon Flores
From 8 am to 1 pm
*Conjunto Vitória Régia Community Centre
From 8 am to 12 noon
RGet the main news from Corumbá, Ladário and MS via WhatsApp from Corumbiency Diary. Click here to join one of our groups.
Charlotte Whitmore is a contributor at Mediarunsearch.co.uk, covering a broad range of topics including news, politics, business, technology, sport, entertainment, and lifestyle. She focuses on delivering clear, balanced reporting and practical information that helps readers stay informed about current events and emerging developments. Her work highlights stories that matter to everyday audiences, with an emphasis on accuracy, relevance, and accessible journalism that keeps readers connected to the issues shaping the UK and beyond.